Wall Street analyst estimates for NeuroSense Therapeutics Ltd. (NRSN): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS).
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-12-02 | $-0.79 | ||
| 2026-06-30 | $-3.90 | $-3.90 | +0.0% |
| 2026-04-06 | $-1.69 | ||
| 2026-03-31 | $-0.23 | $-0.07 | -231.9% |
| 2025-12-17 | $-2.60 | $-0.87 | -197.5% |
| 2025-08-01 | $-0.14 | $-0.22 | +38.1% |
| 2025-04-07 | $-0.06 | $-0.10 | +42.4% |
| 2025-04-04 | $-1.66 |
Valuation Ratios
| Price / Book | -5.76 |
| EV / EBITDA | -1.12 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | $89000 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | -$89000 | 0 | 0 | 0 |
| Research & Development | $898000 | $2.5M | $3.1M | $6.4M | $7.3M | $5.7M | $6.2M |
| Selling, General & Admin | $337000 | $393000 | $2.5M | $7.0M | $4.8M | $4.2M | $4.9M |
| Operating Expenses | $1.2M | $2.9M | $5.6M | $13.5M | $12.0M | $9.9M | $11.1M |
| Operating Income | -$1.2M | -$2.9M | -$5.6M | -$13.6M | -$12.0M | -$9.9M | -$11.1M |
| EBITDA | -$1.3M | -$2.8M | -$2.9M | -$12.2M | -$9.6M | -$9.9M | -$11.1M |
| Interest Expense | $5000 | 0 | $1.2M | $15000 | $550000 | $311000 | 0 |
| Pre-tax Income | -$1.2M | -$2.8M | -$4.0M | -$12.3M | -$10.1M | -$10.2M | -$11.1M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$1.2M | -$2.8M | -$4.0M | -$12.3M | -$10.1M | -$10.2M | -$11.1M |
| EPS | $-4.40 | $-10.20 | $-4.60 | $-21.40 | $-16.60 | $-11.00 | $-8.80 |
| EPS (Diluted) | $-4.40 | $-10.20 | $-4.60 | $-21.40 | $-16.60 | $-11.00 | $-8.80 |
| Shares Outstanding (Diluted) | $272700 | $275950 | $542800 | $575250 | $682000 | $930100 | $1.3M |
Price
| Price | $6.49 |
| Market Cap | $11M |
| Exchange | NASDAQ |
| Country | IL |
Related companies: CLGN · CVKD · ENLV · KLTO · NERV · NRXS · RLYB
Explore sector: Healthcare · Biotechnology
More sections of NRSN: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks